This 5-Star Stock With a Dividend Yield That Tops 4% Is a Buy
Gilead Sciences GILD has relied on its HIV and hepatitis C portfolio to drive profit margins. We think this wide-moat drugmaker’s liver disease portfolio is well positioned to generate continued growth, as are new long-acting HIV treatments, though …